- Home
- ALGS vs ATOS Comparison
ALGS vs ATOS Comparison
Compare ALGS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- ATOS
- Stock Information
- Founded
- ALGS 2018
- ATOS 2009
- Country
- ALGS United States
- ATOS United States
- Employees
- ALGS N/A
- ATOS N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- ATOS Health Care
- Exchange
- ALGS Nasdaq
- ATOS Nasdaq
- Market Cap
- ALGS 118.8M
- ATOS 140.9M
- IPO Year
- ALGS 2020
- ATOS 2012
- Fundamental
- Price
- ALGS $39.84
- ATOS $0.96
- Analyst Decision
- ALGS Strong Buy
- ATOS Strong Buy
- Analyst Count
- ALGS 1
- ATOS 3
- Target Price
- ALGS $75.00
- ATOS $7.00
- AVG Volume (30 Days)
- ALGS 428.8K
- ATOS 952.6K
- Earning Date
- ALGS 11-06-2024
- ATOS 11-12-2024
- Dividend Yield
- ALGS N/A
- ATOS N/A
- EPS Growth
- ALGS N/A
- ATOS N/A
- EPS
- ALGS N/A
- ATOS N/A
- Revenue
- ALGS $5,997,000.00
- ATOS N/A
- Revenue This Year
- ALGS N/A
- ATOS N/A
- Revenue Next Year
- ALGS N/A
- ATOS N/A
- P/E Ratio
- ALGS N/A
- ATOS N/A
- Revenue Growth
- ALGS N/A
- ATOS N/A
- 52 Week Low
- ALGS $6.76
- ATOS $0.73
- 52 Week High
- ALGS $41.64
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- ALGS 80.76
- ATOS 24.57
- Support Level
- ALGS $28.00
- ATOS $1.17
- Resistance Level
- ALGS $35.89
- ATOS $1.30
- Average True Range (ATR)
- ALGS 4.05
- ATOS 0.08
- MACD
- ALGS 0.51
- ATOS -0.02
- Stochastic Oscillator
- ALGS 89.77
- ATOS 1.09
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.